Literature DB >> 25897901

Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients.

Damien Gruson1, Benjamin Ferracin2, Sylvie A Ahn3, Michel F Rousseau3.   

Abstract

Entities:  

Keywords:  BNP; Biomarker; FGF-23; Galectin-3; Heart failure; NT-proBNP; Prognosis; ST2

Mesh：

Substances：

Year:  2015        PMID： 25897901     DOI： 10.1016/j.ijcard.2015.04.074

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  8 in total

1.  Fibroblast growth factor 23 and heart failure: the plot thickens.

Authors:  Orlando M Gutiérrez
Journal:  Nephrol Dial Transplant       Date:  2015-11-27       Impact factor: 5.992

2.  The Association Between Novel Biomarkers and 1-Year Readmission or Mortality After Cardiac Surgery.

Authors:  Jeffrey P Jacobs; Shama S Alam; Sherry L Owens; Devin M Parker; Michael Rezaee; Donald S Likosky; David M Shahian; Marshall L Jacobs; Heather Thiessen-Philbrook; Moritz Wyler von Ballmoos; Kevin Lobdell; Todd MacKenzie; Allen D Everett; Chirag R Parikh; Jeremiah R Brown
Journal:  Ann Thorac Surg       Date:  2018-06-01       Impact factor: 4.330

3.  Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy.

Authors:  Jelmer K Humalda; Sarah Seiler-Muler; Arjan J Kwakernaak; Marc G Vervloet; Gerjan Navis; Danilo Fliser; Gunnar H Heine; Martin H de Borst
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

Review 4.  Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).

Authors:  Rui Dong; Min Zhang; Qunying Hu; Shan Zheng; Andrew Soh; Yijie Zheng; Hui Yuan
Journal:  Int J Mol Med       Date:  2017-12-05       Impact factor: 4.101

Review 5.  Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers.

Authors:  Alexander E Berezin
Journal:  J Circ Biomark       Date:  2016-03-16

Review 6.  Should We Consider the Cardiovascular System While Evaluating CKD-MBD?

Authors:  Merita Rroji; Andreja Figurek; Goce Spasovski
Journal:  Toxins (Basel)       Date:  2020-02-25       Impact factor: 4.546

7.  Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction.

Authors:  Clotilde Roy; Sibille Lejeune; Alisson Slimani; Christophe de Meester; Sylvie A Ahn As; Michel F Rousseau; Amzulescu Mihaela; Audrey Ginion; Benjamin Ferracin; Agnès Pasquet; David Vancraeynest; Christophe Beauloye; Jean-Louis Vanoverschelde; Sandrine Horman; Damien Gruson; Bernhard L Gerber; Anne-Catherine Pouleur
Journal:  ESC Heart Fail       Date:  2020-06-24

8.  Intact fibroblast growth factor 23 levels and outcome prediction in patients with acute heart failure.

Authors:  Anne Cornelissen; Roberta Florescu; Kinan Kneizeh; Christian Cornelissen; Vincent Brandenburg; Elisa Liehn; Alexander Schuh
Journal:  Sci Rep       Date:  2021-07-30       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.